The EMJ Podcast | Bonus Episode
In this podcast, EMJ are joined by Henrik Grönberg, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. Focusing on the topic of precision medicine in prostate cancer, this podcast offers valuable insights into the impact that its widespread implementation could have for patients.
This podcast is supported by Janssen Pharmaceutical Companies of Johnson & Johnson. The views expressed in this podcast are those of the individual speaker and do not necessarily reflect the views of Janssen Pharmaceutical Companies of Johnson & Johnson.
Grönberg addresses key questions throughout the podcast, focusing on the importance of precision medicine in prostate cancer diagnosis and the current guidelines surrounding its application. Providing an expert perspective, Grönberg delves into the different methods used to test for disease pathways in prostate cancer and their value, touching on which individuals should undergo testing to optimise diagnosis and management.
The podcast concludes with a discussion highlighting the importance of raising awareness for testing in individuals with a family risk of cancer, a key factor that could mean early diagnosis and therefore improve prognosis for prostate cancer in many males.
CP-356569, November 2022